Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2021
Press release – For immediate release – 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2021 pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
|Total number of shares||15,467,449|
|Number of real voting rights* (excluding treasury shares**)||15,420,409|
|Theoretical number of voting rights* (including treasury shares**)||15,444, 249|
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88
+33 6 21 10 49 24
Alizé RP (Press)
+33 6 64 18 99 59